Clinical Trial Update: Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome [Phase 2]

View source ↗

Summary

The document reports results from a randomized double-blind Phase 2 trial of allogeneic HB-adMSCs for chronic post-COVID-19 syndrome. Results were posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid
• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• HB-adMSCs (autologous adipose-derived mesenchymal stem cells)

Snippet

Sponsor: Hope Biosciences Research Foundation | Conditions: Post COVID-19 Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2024-11-26